Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A J Scheen

Showing results (291-300 of 787) with videos related to

Pageof 79
Sort By:
Revue Medicale De Liege|November 17, 2009
[Rivaroxaban (Xarelto): new anticoagulant inhibitor of factor Xa]A J Scheen
Revue Medicale De Liege|June 25, 2016
[LIRAGUTIDE AT A DOSE OF 3.0 MG (SAXENDA): NEW INDICATION FOR THE TREATMENT OF OBESITY]A J Scheen
Revue Medicale Suisse|September 28, 2007
[Does a "therapeutic memory" exist in cardiovascular prevention?]A J Scheen
Revue Medicale De Liege|March 9, 2007
[ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?]A J Scheen
Revue Medicale De Liege|July 23, 2005
[Similar reduction in new cases of type 2 diabetes with angiotensin receptor blocker and ACE inhibitor: comparison of meta-analyses of prospective randomised trials]A J Scheen
Diabetes, Obesity & Metabolism|July 2, 2010
Pharmacokinetics of dipeptidylpeptidase-4 inhibitorsA J Scheen
Revue Medicale De Liege|August 6, 2010
[Inertia in clinical practice: causes, consequences, solutions]A J Scheen
Revue Medicale De Liege|July 29, 2014
[Pharmacotherapy in the elderly: primum non nocere!]A J Scheen
Revue Medicale De Liege|September 24, 2013
[Improvised summer travel, illustrative clinical cases]A J Scheen
Diabetes & Metabolism|May 21, 1998
Aggressive weight reduction treatment in the management of type 2 diabetesA J Scheen
Pageof 79

Showing results (291-300 of 787) with videos related to

Sort By:
Pageof 79
Revue Medicale De Liege|November 17, 2009
[Rivaroxaban (Xarelto): new anticoagulant inhibitor of factor Xa]A J Scheen
Revue Medicale De Liege|June 25, 2016
[LIRAGUTIDE AT A DOSE OF 3.0 MG (SAXENDA): NEW INDICATION FOR THE TREATMENT OF OBESITY]A J Scheen
Revue Medicale Suisse|September 28, 2007
[Does a "therapeutic memory" exist in cardiovascular prevention?]A J Scheen
Revue Medicale De Liege|March 9, 2007
[ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?]A J Scheen
Revue Medicale De Liege|July 23, 2005
[Similar reduction in new cases of type 2 diabetes with angiotensin receptor blocker and ACE inhibitor: comparison of meta-analyses of prospective randomised trials]A J Scheen
Diabetes, Obesity & Metabolism|July 2, 2010
Pharmacokinetics of dipeptidylpeptidase-4 inhibitorsA J Scheen
Revue Medicale De Liege|August 6, 2010
[Inertia in clinical practice: causes, consequences, solutions]A J Scheen
Revue Medicale De Liege|July 29, 2014
[Pharmacotherapy in the elderly: primum non nocere!]A J Scheen
Revue Medicale De Liege|September 24, 2013
[Improvised summer travel, illustrative clinical cases]A J Scheen
Diabetes & Metabolism|May 21, 1998
Aggressive weight reduction treatment in the management of type 2 diabetesA J Scheen
Pageof 79